S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Checking in with 5 Bitcoin Stocks Ahead of Bitcoin's Halving
Closing prices for crude oil, gold and other commodities
Lululemon’s P/E Is Back to 2017 Levels: Should You Buy the Dip?
Stock market today: Wall Street dips to send S&P 500 to its longest losing streak since January
Abbott Laboratories Outlook is Healthy: Buy the Dip
Prologis Stock Leading U.S. Logistics Boom
S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Checking in with 5 Bitcoin Stocks Ahead of Bitcoin's Halving
Closing prices for crude oil, gold and other commodities
Lululemon’s P/E Is Back to 2017 Levels: Should You Buy the Dip?
Stock market today: Wall Street dips to send S&P 500 to its longest losing streak since January
Abbott Laboratories Outlook is Healthy: Buy the Dip
Prologis Stock Leading U.S. Logistics Boom
S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Checking in with 5 Bitcoin Stocks Ahead of Bitcoin's Halving
Closing prices for crude oil, gold and other commodities
Lululemon’s P/E Is Back to 2017 Levels: Should You Buy the Dip?
Stock market today: Wall Street dips to send S&P 500 to its longest losing streak since January
Abbott Laboratories Outlook is Healthy: Buy the Dip
Prologis Stock Leading U.S. Logistics Boom
S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Checking in with 5 Bitcoin Stocks Ahead of Bitcoin's Halving
Closing prices for crude oil, gold and other commodities
Lululemon’s P/E Is Back to 2017 Levels: Should You Buy the Dip?
Stock market today: Wall Street dips to send S&P 500 to its longest losing streak since January
Abbott Laboratories Outlook is Healthy: Buy the Dip
Prologis Stock Leading U.S. Logistics Boom
NASDAQ:UBX

Unity Biotechnology (UBX) Stock Price, News & Analysis

$1.50
-0.02 (-1.31%)
(As of 04/17/2024 ET)
Today's Range
$1.50
$1.52
50-Day Range
$1.50
$1.99
52-Week Range
$1.50
$3.82
Volume
28,480 shs
Average Volume
88,356 shs
Market Capitalization
$25.25 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$6.00

Unity Biotechnology MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
298.7% Upside
$6.00 Price Target
Short Interest
Healthy
2.00% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.60
Upright™ Environmental Score
News Sentiment
0.59mentions of Unity Biotechnology in the last 14 days
Based on 6 Articles This Week
Insider Trading
Selling Shares
$2,023 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($2.66) to ($1.98) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.17 out of 5 stars

Medical Sector

141st out of 914 stocks

Pharmaceutical Preparations Industry

46th out of 404 stocks

UBX stock logo

About Unity Biotechnology Stock (NASDAQ:UBX)

Unity Biotechnology, Inc., a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. The company's lead drug candidate includes UBX1325, which is phase II clinical trial for the treatment of age-related diseases of the eye, including diabetic macular edema, age-related macular degeneration, and diabetic retinopathy. It also develops UBX1967 for the treatment of ophthalmologic diseases; UBX2050, a human anti-Tie2 agonist monoclonal antibody for the treatment of age-related eye diseases; and UBX2089, a a-Klotho hormone drug candidate for multiple neurology indications. The company was formerly known as Forge, Inc. and changed its name to Unity Biotechnology, Inc. in January 2015. Unity Biotechnology, Inc. was incorporated in 2009 and is headquartered in South San Francisco, California.

UBX Stock Price History

UBX Stock News Headlines

Don’t expose yourself to stocks during the week
The S&P 500 just crossed below the 200 day moving average… The Nasdaq is bleeding out… Are we headed for a recession?! If you’ve been in the stock market the last few months, it hasn’t been fun… But what if I told you there was a way to target “BONUS” income just by doing a unique type of trade over the weekend? When the markets are closed. And volatility is minimal.
Unity Biotechnology, Inc. (0YC0.L)
UBX Mar 2024 2.000 call
Unity Biotechnology Inc (UBX)
Don’t expose yourself to stocks during the week
The S&P 500 just crossed below the 200 day moving average… The Nasdaq is bleeding out… Are we headed for a recession?! If you’ve been in the stock market the last few months, it hasn’t been fun… But what if I told you there was a way to target “BONUS” income just by doing a unique type of trade over the weekend? When the markets are closed. And volatility is minimal.
Wedbush Upgrades Unity Biotechnology (UBX)
20 Foods Consumed By Longest Living People Every Day
See More Headlines
Receive UBX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Unity Biotechnology and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/10/2021
Today
4/17/2024
Next Earnings (Estimated)
5/14/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:UBX
Fax
N/A
Employees
22
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$6.00
High Stock Price Target
$8.00
Low Stock Price Target
$4.00
Potential Upside/Downside
+296.8%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$-59,930,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$240,000.00
Book Value
$4.71 per share

Miscellaneous

Free Float
15,963,000
Market Cap
$25.37 million
Optionable
Optionable
Beta
0.87
Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Key Executives

  • Dr. Anirvan Ghosh Ph.D. (Age 60)
    CEO & Director
    Comp: $1.08M
  • Dr. Nathaniel E. David A.B. (Age 56)
    Ph.D., Co-Founder & Executive Director
    Comp: $40k
  • Ms. Lynne Marie Sullivan (Age 57)
    CFO & Head of Corporate Development
    Comp: $730.82k
  • Dr. Jan M. van Deursen
    Founder
  • Dr. Judith Campisi Ph.D.
    Founder
  • Mr. Daohong Zhou M.D.
    Founder
  • Mr. Nathan Guz Ph.D.
    Vice President of Operations
  • Mr. Alexander Azoy (Age 48)
    Chief Accounting Officer & Principal Accounting Officer
  • Dr. Przemyslaw Sapieha Ph.D.
    Chief Scientist
  • Mr. Alexander Hieu Nguyen J.D. (Age 47)
    General Counsel & Corporate Secretary

UBX Stock Analysis - Frequently Asked Questions

Should I buy or sell Unity Biotechnology stock right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Unity Biotechnology in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" UBX shares.
View UBX analyst ratings
or view top-rated stocks.

What is Unity Biotechnology's stock price target for 2024?

2 Wall Street analysts have issued 1-year price targets for Unity Biotechnology's shares. Their UBX share price targets range from $4.00 to $8.00. On average, they anticipate the company's stock price to reach $6.00 in the next twelve months. This suggests a possible upside of 298.7% from the stock's current price.
View analysts price targets for UBX
or view top-rated stocks among Wall Street analysts.

How have UBX shares performed in 2024?

Unity Biotechnology's stock was trading at $1.93 at the beginning of the year. Since then, UBX stock has decreased by 22.0% and is now trading at $1.5050.
View the best growth stocks for 2024 here
.

When is Unity Biotechnology's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024.
View our UBX earnings forecast
.

How were Unity Biotechnology's earnings last quarter?

Unity Biotechnology, Inc. (NASDAQ:UBX) posted its earnings results on Wednesday, November, 10th. The company reported ($3.00) EPS for the quarter, topping the consensus estimate of ($3.60) by $0.60.

When did Unity Biotechnology's stock split?

Unity Biotechnology shares reverse split before market open on Thursday, October 20th 2022. The 1-10 reverse split was announced on Thursday, October 20th 2022. The number of shares owned by shareholders was adjusted after the market closes on Thursday, October 20th 2022. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

What other stocks do shareholders of Unity Biotechnology own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Unity Biotechnology investors own include NIO (NIO), Inseego (INSG), NVIDIA (NVDA), Editas Medicine (EDIT), Advanced Micro Devices (AMD), VBI Vaccines (VBIV), Enphase Energy (ENPH), Sorrento Therapeutics (SRNE) and OPKO Health (OPK).

When did Unity Biotechnology IPO?

Unity Biotechnology (UBX) raised $85 million in an initial public offering on Thursday, May 3rd 2018. The company issued 5,000,000 shares at $16.00-$18.00 per share. Goldman Sachs, Morgan Stanley and Citigroup served as the underwriters for the IPO and Mizuho Securities was co-manager.

How do I buy shares of Unity Biotechnology?

Shares of UBX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:UBX) was last updated on 4/17/2024 by MarketBeat.com Staff

From Our Partners